SEARCH

SEARCH BY CITATION

References

  • 1
    Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25:305313.
  • 2
    Clark LT, Emerole O. Coronary heart disease in African Americans: primary and secondary prevention. Cleve Clin J Med. 1995;62:285292.
  • 3
    American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas , TX : American Heart Association, 2001.
  • 4
    Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992;152:5664.
  • 5
    Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program: mortality by race sex and blood pressure level. A further analysis. J Commun Health. 1984;9:314327.
  • 6
    Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:25622571.
  • 7
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment of older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:32553264.
  • 8
    Systolic Hypertension in the Elderly Program Cooperative Research Group. Implications of the Systolic Hypertension in the Elderly Program. Hypertension. 1993;21:335343.
  • 9
    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:9951003.
  • 10
    Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:10041010.
  • 11
    Merck reports additional subgroup analyses from LIFE study with investigational use of Cozaar. Merck News Release, April 11, 2002.
  • 12
    Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA. 2001;285:27192728.
  • 13
    Sica DA, Douglas JG. The African American Study of Kidney Disease and Hypertension (AASK): new findings. J Clin Hypertens. 2001;3:244251.
  • 14
    Wright JT, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2002;162:16361643.
  • 15
    Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK Trial. JAMA. 2002;288:24212431.
  • 16
    Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342360.
  • 17
    Grimm RH, Margolis KL, Papademetriou V, et al. Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2001;37:1927.
  • 18
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):29812997.
  • 19
    Wright JT, Cushman WC, Davis BR, et al. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience. Control Clin Trials. 2001;22:659673.
  • 20
    Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646661. 2.
  • 21
    Flack JM, Bledsoe K. Combination antihypertensive drug therapy: a therapeutic option long overdue. Am Fam Phys. 2000;61:29742975.
  • 22
    The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program. NIH Publication No. 98-4080. November 1997.
  • 23
    Saunders E. Tailoring treatment to minority patients. Am J Med. 1990;88(Suppl 3B):21S23S.
  • 24
    American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(Suppl 1):S33S50.
  • 25
    Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. Available at: http:www.acc.orgclinicalguidelinesfailurehfindex.htm. Accessed August 13, 2002.
  • 26
    Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:13581365.
  • 27
    Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609616.
  • 28
    Smith SC, Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation. 2001:104:15771579.